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OBJECTIVES: Catheter-based renal denervation (RDN) is a new approach to treat
resistant hypertension, a condition that affects approx. 10-15% of hypertensives.
Our objective was to develop a decision-analytic model to assess clinical and cost-
effectiveness of (RDN) from the U.K. National Health Service perspective.
METHODS: A 34-state Markov model predicted cardiovascular endpoints, mortal-
ity, quality-adjusted life years (QALYs), and costs. Input parameters were derived
from multivariate risk equations and other published sources, including the re-
cently published NICE Hypertension Guidance. We evaluated the impact of a 32
mmHg reduction in systolic blood pressure (SBP), from a baseline SBP of 178 mmHg,
in a 42.5% female, 34% diabetic, and 16% smoking cohort with a mean age of 58, as
observed in the Symplicity HTN-2 randomized controlled trial. We calculated ten-
year relative risks and the lifetime incremental cost-effectiveness ratio (ICER) in
£/QALY discounted at 3.5% per year for numerator and denominator. RESULTS:
Relative risks for clinical endpoints were 0.70 for stroke, 0.68 for myocardial infarc-
tion, 0.78 for all coronary heart disease, 0.79 for heart failure, 0.72 for end-stage
renal disease, 0.65 for cardiovascular and 0.82 for all-cause mortality, respectively.
The ICER was £4,870/QALY. CONCLUSIONS: Our model projections suggest RDN
reduces and delays cardiovascular events and is a cost-effective therapy in the U.K.
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ECONOMICAL ASPECTS OF THE REIMBURSEMENT OF EXTRACORPOREAL
PHOTOPHERESIS (ECP) IN TREATMENT OF PATIENTS WITH GRAFT-VERSUS-
HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) WHO ARE REFRACTORY TO STEROID TREATMENT
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OBJECTIVES: Determining cost-effectiveness of ECP in the treatment of patients
with steroid-refractory GvHD after allogeneic HCT, as well as the impact of its
reimbursement on the Polish public payer expenditures. METHODS: The evalua-
tion of the cost-effectiveness of ECP was conducted separately for children/adults
with acute/chronic steroid-refractory GvHD by means of Markov decision model.
Due to the lack of standards of treatment for this group of patients and adequate
clinical studies, analysis was performed without a comparator. Polish cost data
were estimated from the perspective of the public payer (NHF). Discount rates 5%
for costs and 3.5% for health outcomes were used. There was also calculated extra
cost incurred by NHF caused by ECP reimbursement. Two scenarios were consid-
ered: the existing (no ECP reimbursement) and the new (ECP reimbursed) on the
2-year time horizon. For assuming current expenses incurred on GvHD treatment
data published by NHF were used. Savings resulting from the decreased number of
other health services used in GvHD treatment were not considered, so incremental
cost consists merely of the costs of ECP procedure performed. Target population
was estimated at 37-38 patients. RESULTS: The most favorable ratio of health
benefits to costs of therapy in 3-year time horizon was achieved for treatment of
adult patients with acute GvHD – CER ratio 24,103.30 PLN/LY. Others ratios of health
benefits to costs are: 26,772.15 PLN/LY for children with chronic GvHD; 30,473.46
PLN/LY for adults with chronic GvHD and 35,854.39 PLN/LY for children with acute
GvHD. After ECP reimbursement, annual expenses of the public payer on the treat-
ment of acute and chronic GvHD are going to grow by 1,224,736-1,269,300 PLN
(47.92%-49.66%) in the following years of the time horizon. CONCLUSIONS: ECP
seems to be a cost-effective therapy for patients with steroid-refractory, acute and
chronic GvHD with limited impact to Polish public payer budget.
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OBJECTIVES: Heart Failure (HF) admission costs are an important component of
health care resource utilization through the developed world and especially in the
above 65 age group. Cardiac Resynchronization Therapy (CRT) devices have been
proven to reduce HF admissions in indicated patients. Optimal CRT performance
requires periodic device re-programming using simultaneously perfromed cardiac
ultrasounds; however, newer CRT device algorithms continuously and automati-
cally re-program. Ultimately, this continuous optimization maximizes CRT re-
sponse. We approximated health care system cost-savings when aCRT devices are
used over “Traditional” CRT from the perspective of 4 developed geographies.
METHODS: A stratified propensity score analysis estimated Clinical Composite
Score (CCS) differences between technologies. HF admissions/patient-year were
calculated using average rates by CCS. HF admission costs for Payers were obtained
for the UK, Germany, Australia and Canada. Admission rates were extrapolated for
7 years (average CRT-D battery life). RESULTS: Basecase analyses indicate that
aCRT patients could experience an estimated 0.21 less admissions per device im-
planted (17% overall admission reduction) leading to a direct saving per device of
GBP699 (95% CI GBP322-GBP1,001) in the UK; EUR522 (95% CI EUR185-EUR791) in
Germany; AUD1,211 (95% CI AUD427-AUD1,834) in Australia; and CAD1,580 (95% CI
CAD560-CAD2,395) in Canada. Sensitivity analyses which varied the timeframe of
admission rate by CCS and used 0-12 month CCS admission rates estimated a mean
number of avoided HF admissions could reach 0.67 (21.51% overall admission
reduction) which in turn may result in a near tripling of the payer savings men-
tioned above. CONCLUSIONS: aCRT devices appear significantly cost-saving
throughout diverse payment settings; estimates are likely understated since they
include neither follow-up visits (which may be avoided with aCRT) nor avoided
cardiac ultrasounds nor well-documented effects of HF disease progression. CRT
already is proven to reduce mortality and increase QoL at a highly cost-effective
level. aCRT, therefore, certainly has the potential to further improve these out-
comes.
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OBJECTIVES: This prospective study assessed the costs and cost-effectiveness of
routine HIV testing in non traditional settings using Oral fluid-based HIV testing
and a fourth-generation assay. METHODS: HIV tests were offered to patients aged
16-65 over 3 months in 4 settings: Emergency Department, Acute Care Unit, Der-
matology Outpatients and Primary Care in London. We assessed and compared the
costs and the cost-effectiveness ratio of screening in terms of costs for newly
diagnosed HIV-infected patients using the real data derived from each setting.
Additionally, the Survey of Prevalent HIV Infections Diagnosed (SOPHID) was used
to estimate the number of undiagnosed individuals attending each setting over one
year. A sensitivity analysis was run using the SOPHID data to simulate the costs
and cost-effectiveness of the HIV screening in different scenarios, changing the
prevalence and the compliance rates. RESULTS: HIV testing in non traditional
settings cost £19,056.31 per newly diagnosed patient. Using the SOPHID data and
assuming the same compliance rate, the cost for a newly diagnosed patient is
£4,460.59. In the best scenario, assuming 100% compliance, the cost will decrease to
£2,940 per patient. These figures do not take into account the additional cost sav-
ings that may result from earlier diagnosis of HIV-infected individuals.
CONCLUSIONS: The results of the study are really encouraging and suggest that a
screening programme in a high prevalence area could identify HIV-infected pa-
tients at a very low cost. Earlier diagnosis of HIV infection may subsequently have
further cost benefits in terms of aversion of incident infections and early treatment
of infected individuals.
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OBJECTIVES: CRT for Heart Failure (HF) Patients is established as cost-effective.
Nevertheless, optimal functionality requires periodic device re-programming (“op-
timization”) using data from contemporaneous cardiac ultrasounds. Newer CRT
device algorithms continuously re-program, increasing the number of patients
responding to therapy while eliminating the ultrasounds. Maximizing CRT re-
sponse further reduces HF re-admissions. We sought to estimate payer savings
stemming from aCRT device use. METHODS: A stratified propensity score analysis
was performed to estimate response rates, as measured by Clinical Composite
Score (CCS), between aCRT and Traditional CRT. Rates of future HF admissions
were estimated by 6-month CCS using pooled patient-level data from prior CRT
studies. HF admission costs were obtained from the 2009 Medicare Fee Schedule.
Resource utilization and costs were modeled for 7 years following implantation
(average CRT-D Battery Life). RESULTS: Basecase Analyses indicate that aCRT pa-
tients could experience an estimated 0.05 fewer HF hospitalizations in the first 6
months, 0.01 fewer in the next 6 months, and 0.15 fewer in years 2-7 (17% overall
admission reduction). At a cost of $7,977/admission, aCRT is estimated to save
$1,477 per patient; factoring in reductions in cardiac ultrasounds, savings increase
to $1,644 (95% CI $675 – $2,346). Sensitivity Analyses using 0-12 month admission
rates by CCS extrapolated through 7 years estimate that the mean number of
avoided HF admissions could reach 0.67 (21.51% overall admission reduction) –
translating to $5,345 saved. CONCLUSIONS: aCRT Devices appear cost-saving to
payers; Base Case estimates are likely understated since they include neither any
other medical procedures that may be performed in parallel to the cardiac ultra-
sound nor the well-documented effects of HF disease progression. Further research
could better quantify the amount of savings aCRT devices can deliver; since CRT
generally reduces mortality and increases QoL, aCRT may have the potential to
improve the cost-effectiveness of the entire device class.
PMD28
COMPARING THE COST AND DIAGNOSTIC EFFICIENCY OF GADOXETIC ACID-
ENHANCED MRI VERSUS EXTRACELLULAR CONTRAST MEDIA-ENHANCED MRI
AND MULTIDETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH
SUSPECTED HEPATOCELLULAR CARCINOMA IN THAILAND AND KOREA
Holtorf AP1, Bergmann K2, Kim MJ3, Phongkitkarun S4, Sobhonslidsuk A5, Rinde H6,
Lee JM7
1Health Outcomes Strategies, GmbH, Basel, Switzerland, 2Bayer HealthCare, Berlin, Germany,
A349V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
3Severance Hospital, Seoul, South Korea, 4Ramathibodi Hospital Mahidol University, Bangkok,
Thailand, 5Ramathibodi Hospital, Bangkok, Thailand, 6BioBridge Strategies, Binningen, BL,
Switzerland, 7Seoul National University Hospital, Seoul, South Korea
OBJECTIVES: To compare the clinical and cost consequences of Gadoxetic Acid-
enhanced magnetic resonance imaging (PV-MRI) to extracellular contrast media-
enhanced MRI (ECCM-MRI) and Multidetector Computed Tomography (MD-CT) in
patients with suspected hepatocellular carcinoma (HCC) in South Korea and
Thailand. METHODS: The clinical pathway of patients with suspected HCC from
the initial imaging procedure (PV-MRI, ECCM-MRI or MD-CT) to the confirmed treat-
ment decision was presented in an economic decision-tree model. The model com-
pared payer relevant costs of the three diagnostic procedures as first line imaging
for suspected HCC and the subsequent costs to reach a confirmed treatment deci-
sion. The probabilities and resource consumptions were estimated and validated
by clinical experts through a Delphi panel process. Costs for diagnostic and treat-
ment options were derived from published sources. RESULTS:Using PV-MRI as first
imaging procedure in patients with suspected HCC evokes total cost of US$ 3,098/
patient in Korea. This is 0.1% higher than the costs for MD-CT (US$ 3,094/patient),
but 9.9% lower (US$ 306) than the costs of ECCM-MRI (US$ 3,405/patient). In Thai-
land, PV-MRI (US$ 702/patient) is the least costly alternative compared to ECCM-
MRI (US$ 930/patient) and MDCT (US$ 872/patient) and leads to cost savings of US$
228 US$and US$ 170, respectively. The higher acquisition cost of PV-MRI are more
than compensated by the cost saving achieved through the reduced need for con-
firmatory imaging procedures and the reduced need for changes in the surgical
protocol during resection. CONCLUSIONS: Using PV-MRI compared to ECCM-MRI
and MD-CT for the first imaging in patients with suspected HCC leads to relevant
cost savings for the statutory health insurance in both countries. The impact on
health outcomes (e.g. mortality, quality of life) and total cost needs to be shown in
an extended study approach.
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COMPARING THE ECONOMIC IMPACT OF PROSTHESIS CHOICE IN
UNICOMPARTMENTAL KNEE ARTHROPLASTY PROCEDURES: DEVELOPMENT OF
AN ECONOMIC MODEL
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OBJECTIVES: The purpose of this study was to develop an economic impact model
to calculate and compare the net present cost of unicompartmental knee prosthe-
ses. These implants are used in knee arthroplasty procedures and are one of the
key cost drivers of the overall procedural cost. METHODS: A model was developed
using revision rates published in the Australian National Joint Replacement Regis-
try, to calculate the economic impact on health care systems. It was assumed that
the cost of the primary procedure remained constant regardless of the implant
used. Only prostheses reporting more than 1 year follow-up (n14) were included.
A sensitivity analysis was performed to examine the influence of varying time
horizons and discount rates. RESULTS: From a societal perspective, comparing the
predicted number of revisions and net present cost of revisions resulted in sub-
stantial differences between implants. The longer the time horizon, the greater the
differences reported between implants. The effect of different discount rates was
less than the effect of different time horizons. For a one time cohort of 2,500 pa-
tients, a time horizon of 5 years, a discount rate of 3.5% and a national reimburse-
ment rate for revision for an unicompartmental knee replacement of 10,000 Euros,
the net present cost for a national health care system could be as high as 4,500,000
Euros (all patients treated with the implant with the highest revision rate) or as low
as 1,200,000 Euros (all patients treated with the implant with the lowest revision
rate). CONCLUSIONS: This model may be utilized by health care systems or payers
to evaluate the economic impact of choosing implants with low revision rates.
Furthermore, the model allows for evidence-based pricing discussions. This study
provides important information, regardless of geography, for health systems and
payers to consider when selecting an implant for unicompartmental knee arthro-
plasty procedures.
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OBJECTIVES: Typical cost-effectiveness studies of CSII therapy focus on long-term
health-economic outcomes, with little emphasis on immediate clinical and eco-
nomic benefits which underpin long-term complication-related savings. The ob-
jective was therefore to evaluate the short-term health-economic outcomes of CSII
versus multiple daily injections (MDI), using best practice modelling methodology
with a focus on changes in glycosylated haemoglobin (HbA1c), severe hypoglycemic
events (SHE), insulin consumption and complication and insulin related (CIR) costs.
METHODS: The SWITCH costing model was developed based on regression equa-
tions for changes in HbA1c and SHE. Model inputs were derived from best available
evidence. Analysis was performed from a health care payer’s perspective for the
Netherlands. Model outputs included clinical benefits and potential reductions in
CIR costs. Sensitivity analysis determined the robustness of the results. RESULTS:
In a cohort representative of Netherlands, switching patients with poorly con-
trolled HbA1c on MDI [average HbA1c 9%; 0.2 SHE per patient year (PPY)] to CSII
results in the following calculated improvements PPY: 50% SHE potentially avoided
[€65 expenditure reduction (ER)], insulin dose reduction of 7,597 IU [€141 ER]; and a
relative HbA1c reduction of 12% [€406 ER]. The total calculated short-term improve-
ment in this subgroup is associated with potential savings in CIR cost of €612 PPY.
Similarly, switching patients with frequent SHE on MDI [average HbA1c 7%; 1.0 SHE
PPY] to CSII results in the following calculated improvements PPY: 80% SHE poten-
tially avoided [€523 ER], insulin dose reduction of 3,799 IU PPY [€71 ER]; and a
relative HbA1c reduction of 1% [€10 ER]. The total calculated short-term improve-
ment in this subgroup is associated with potential savings in CIR cost of €603 PPY.
CONCLUSIONS: In addition to long-term benefits; depending on baseline values,
switching patients from MDI to CSII potentially results in improved clinical out-
comes with significant reductions in short-term CIR costs.
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OBJECTIVES: To analyze cost, surgical time, hospitalization time, bleeding and
pain scores postoperatively, regarding patients who underwent thyroidectomy us-
ing vessel sealer system or harmonic scalpel technique compared to convencional.
METHODS: A retrospective study. Thyroidectomies performed between 2007 and
2010 (n  460), segmented by conventional or minimally invasive technique, used
to vessel sealer system or harmonic scalpel. Were analyzed: sex, age, principal
diagnosis, type of procedure (total thyroidectomy with or without lymphadenec-
tomy, thyroidectomy with or without lymphadenectomy). The outcomes analyzed
were duration of surgery, hospital stay, need for blood transfusions and pain score.
The conclusions were based on a significance level of 5% and statistical analyzes
were performed using the software R. RESULTS: The outcome duration of surgery,
the use of vessel sealer system resulted in increased duration of surgery about 47
minutes when compared to using the conventional technique (p0.001) and the use
of harmonic scalpel led to a reduction of the length mean surgery in approximately 32
minutes compared to the conventional technique (p0.001). Patients who used vessel
sealer system or harmonic scalpel had cost more than in patients with the conven-
tional technique. In relation to the outcome scores of pain and blood transfusion there
was no difference between the techniques.CONCLUSIONS: The use of harmonic scal-
pelwasfavorableintermsofreducingthedurationofsurgery,butwasn’tobservedimpact
on length of hospital stay and cost of the procedure was significantly higher (28%). Using
the vessel sealing system are no results in favorable outcomes assessed and the cost
increase was significant compared to the conventional technique.
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OBJECTIVES: Aortic valve replacement (AVR) the most common heart valve oper-
ation, accounts for a majority of all valve surgery performed in the elderly. Mini-
invasive aortic valve replacement (MiAVR) has several advantages over full ster-
notomy, mainly less surgical trauma, decreased blood loss, lower mortality and
faster recovery. However, it’s also associated with some draw-backs, as an in-
creased technical complexity and higher aortic cross-clamp circulation times
(CCTs). Perceval S is a new aortic valve which is implanted without need for sutur-
ing and a collapsed profile, thus allowing a significant reduction of cross-clamping
times, an independent risk factor for worse outcomes, allowing to expand the pool
of operable patients with MiAVR. Aim of this simulation study was to predict costs
and outcomes of isolated AVR procedures associated with this new valve in 4
European countries (Italy, France, Germany, and UK), as compared to traditional
valve implants, from the cost perspective of the hospital. METHODS: A probabilis-
tic, patient-level simulation model was fully coded in WinBugs, permitting a seam-
less integration of parameter estimation and outcomes prediction, which was en-
tirely based on the associated CCTs and on the surgical technique (mini-invasive
vs. full sternotomy), through published correlations. Unit cost were retrieved from
official and literature sources for all countries. Besides the incorporated probabi-
listic sensitivity analysis, a series of deterministic sensitivity analyses was
performed. RESULTS: The model predicts less complications with the use of the
Perceval S valve, and savings (valve cost excluded) ranging from slightly less than
6,000 € (Italy) to 6,700 £ (UK), mainly related to a reduction in surgery costs and
ICU/hospital bed days. Extensive sensitivity analyses confirm the robustness of
such findings. CONCLUSIONS: Reduced costs for the surgical procedure, shorter
hospital stay and complications mangament wtih Perceval S offset its increased
cost in all analysed countries.
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PLANNING FOR PATIENTS WITH COLORECTAL CANCER LIVER METASTASES
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OBJECTIVES: To compare Gadoxetic Acid-enhanced MRI (PV-MRI) with extracellu-
lar contrast media-enhanced MRI (ECCM-MRI) and 3-phase MD-CT (MD-CT) in the
planning of surgery for patients with colorectal cancer liver metastases (CRCLM).
METHODS: A decision-tree model was used. The probabilities were collected and
validated by radiologists and liver surgeons in Germany, Italy and Sweden using a
Delphi panel process. Cost was derived from published sources and the mean costs
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